About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pelacarsen

Company: Novartis Pharmaceuticals
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 15, 2026

Trial details

Recruiting NCT NCT05646381

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Not yet reported Novartis Pharmaceuticals 502 participants Est. completion 2030-03-12 140 sites Stand-alone

Other conditions: Aortic Stenosis
View official trial listing →
Completed NCT NCT03070782

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

Not yet reported Akcea Therapeutics 286 participants Est. completion 2018-11-13 32 sites

Cardiovascular disease Other conditions: Elevated Lipoprotein(a)
View official trial listing →
Completed NCT NCT04023552

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Not yet reported Novartis Pharmaceuticals 8323 participants Est. completion 2026-07-16 902 sites Stand-alone

Cardiovascular disease
View official trial listing →
Withdrawn NCT NCT04993664

Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)

Not yet reported University Medical Centre Ljubljana Est. completion 2022-10-01 1 site Stand-alone

Other conditions: Acute Coronary Syndrome, Lipoproteinemia, Inflammation, Genetic Polymorphisms
View official trial listing →
Completed NCT NCT05026996

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Not yet reported Novartis Pharmaceuticals 17 participants Est. completion 2022-10-19 1 site Stand-alone

Other conditions: Hepatic Impairment
View official trial listing →
Completed NCT NCT05305664

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Not yet reported Novartis Pharmaceuticals 51 participants Est. completion 2025-01-28 13 sites Stand-alone

Other conditions: Hyperlipoproteinemia(a)
View official trial listing →
Completed NCT NCT05337878

A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants

Not yet reported Ionis Pharmaceuticals, Inc. 29 participants Est. completion 2019-12-18 1 site Stand-alone

Other conditions: Healthy Participants
View official trial listing →
Active, not recruiting NCT NCT05900141

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Not yet reported Novartis Pharmaceuticals 41 participants Est. completion 2028-08-24 9 sites Stand-alone

Other conditions: Hyperlipoproteinemia (a)
View official trial listing →
Completed NCT NCT06267560

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Not yet reported Novartis Pharmaceuticals 422 participants Est. completion 2026-03-25 96 sites Stand-alone

Cardiovascular disease
View official trial listing →
Active, not recruiting NCT NCT06813911

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Not yet reported Novartis Pharmaceuticals 246 participants Est. completion 2028-02-29 94 sites

Cardiovascular disease
View official trial listing →
Active, not recruiting NCT NCT06875973

Pelacarsen Roll-over Extension Program

Not yet reported Novartis Pharmaceuticals 599 participants Est. completion 2030-12-08 89 sites Stand-alone

Cardiovascular disease
View official trial listing →
Available NCT NCT07000695

Managed Access Programs for TQJ230, Pelacarsen

Novartis Pharmaceuticals

Cardiovascular disease
View official trial listing →
Active, not recruiting NCT NCT07517263

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Not yet reported Novartis Pharmaceuticals 5700 participants Est. completion 2030-01-09 646 sites Stand-alone

Cardiovascular disease
View official trial listing →
Withdrawn NCT NCT07625306

Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

Not yet reported Novartis Pharmaceuticals Est. completion 2029-01-22 Stand-alone

Other conditions: Acute Coronary Syndrome (ACS)
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT05900141

Also known as: Pelacarsen, TQJ230

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.